Telix Pharmaceuticals Limited Unsponsored ADR (TLX) Stock Statistics & Valuation Metrics

Telix Pharmaceuticals Limited Unsponsored ADR has a market cap or net worth of $3.22B. The enterprise value is $4.44B.

Market Cap

$3.22B

Enterprise Value

$4.44B

Telix Pharmaceuticals Limited Unsponsored ADR has 340,330,380 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

340,330,380

Owned by Insiders

―

Owned by Institutions

0.11%

Telix Pharmaceuticals Limited Unsponsored ADR’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is 1.80%.

Return on Equity (ROE)

-0.02

Return on Assets (ROA)

-0.01

Return on Invested Capital (ROIC)

1.80%

Return on Capital Employed (ROCE)

0.02

Revenue Per Employee

685.57K

Profits Per Employee

―

Employee Count

1,152

Asset Turnover

0.67

Inventory Turnover

9.99

The current PE Ratio of Telix Pharmaceuticals Limited Unsponsored ADR is 97.04. Telix Pharmaceuticals Limited Unsponsored ADR’s PEG ratio is -0.43.

PE Ratio

97.04

PS Ratio

3.56

PB Ratio

6.46

Price to FCF

-53.91

Price to Operating Cash Flow

-235.65

PEG Ratio

-0.43

In the last 12 months, Telix Pharmaceuticals Limited Unsponsored ADR had revenue of 789.77M and earned ― in profits. Earnings per share was -0.02.

Revenue

789.77M

Gross Profit

419.47M

Operating Income

17.46M

Pretax Income

-5.17M

Net Income

―

EBITDA

52.30M

Earnings Per Share (EPS)

-0.02

In the last 12 months, operating cash flow was -11.76M and capital expenditures -45.38M, giving a free cash flow of -57.14M billion.

Operating Cash Flow

-11.76M

Free Cash Flow

-57.14M

Free Cash Flow per Share

-0.17

Telix Pharmaceuticals Limited Unsponsored ADR pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-1.79%

Earnings Yield

1.00%

Beta

1.49

52-Week Price Change

-4.94%

50-Day Moving Average

10.86

200-Day Moving Average

10.01

Relative Strength Index (RSI)

46.96

Average Volume (3m)

346.59K

Telix Pharmaceuticals Limited Unsponsored ADR upcoming earnings date is Feb 19, 2027, TBA (Not Confirmed).

Last Earnings Date

Aug 19, 2026

Next Earnings Date

Feb 19, 2027

Ex-Dividend Date

―

Telix Pharmaceuticals Limited Unsponsored ADR as a current ratio of 1.43, with Debt / Equity ratio of 112.45%

Current Ratio

1.43

Quick Ratio

1.27

Debt to Market Cap

0.16

Net Debt to EBITDA

6.22

Interest Coverage Ratio

0.48

In the past 12 months, Telix Pharmaceuticals Limited Unsponsored ADR has paid 1.83M in taxes.

Income Tax

1.83M

Effective Tax Rate

-0.35

Telix Pharmaceuticals Limited Unsponsored ADR EV to EBITDA ratio is 118.35, with an EV/FCF ratio of -61.39.

EV to Sales

4.06

EV to EBITDA

118.35

EV to Free Cash Flow

-61.39

EV to Operating Cash Flow

-268.78

Telix Pharmaceuticals Limited Unsponsored ADR has $251.82M in cash and marketable securities with $579.64M in debt, giving a net cash position of -$327.83M billion.

Cash & Marketable Securities

$251.82M

Total Debt

$579.64M

Net Cash

-$327.83M

Net Cash Per Share

-$0.96

Tangible Book Value Per Share

-$0.29

Gross margin is 52.14%, with operating margin of -0.78%, and net profit margin of 3.69%.

Gross Margin

52.14%

Operating Margin

-0.78%

Pretax Margin

3.19%

Net Profit Margin

3.69%

EBITDA Margin

3.43%

EBIT Margin

-0.78%

The average price target for Telix Pharmaceuticals Limited Unsponsored ADR is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$20.00

Price Target Upside

105.66% Upside

Analyst Consensus

Moderate Buy

Analyst Count

2

Revenue Growth Forecast

33.78%

EPS Growth Forecast

198.49%

Smart Score

6

AI Score

57